Do you guys remember when a year ago or so, in a GILD conf call, the CEO or CSO said when asked on M&As opportunities, that they had lost the train on CAR-T? I expected a deal in oncology but not in CAR-T. I bet they think they can charge big for these drugs, even not for everybody